[go: up one dir, main page]

BR112021021826A8 - Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition - Google Patents

Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition

Info

Publication number
BR112021021826A8
BR112021021826A8 BR112021021826A BR112021021826A BR112021021826A8 BR 112021021826 A8 BR112021021826 A8 BR 112021021826A8 BR 112021021826 A BR112021021826 A BR 112021021826A BR 112021021826 A BR112021021826 A BR 112021021826A BR 112021021826 A8 BR112021021826 A8 BR 112021021826A8
Authority
BR
Brazil
Prior art keywords
apremilast
inhibitor
inhibition
disease
treatment
Prior art date
Application number
BR112021021826A
Other languages
Portuguese (pt)
Other versions
BR112021021826A2 (en
Inventor
Gilles Buchwalter
Lisa Beebe
Mary Adams
Henry Schafer Peter
Robert Plenge
Te-Chen Tzeng
Tiffany Carr
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112021021826A2 publication Critical patent/BR112021021826A2/en
Publication of BR112021021826A8 publication Critical patent/BR112021021826A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

terapias combinadas compreendendo apremilaste e inibidores de tyk2. são fornecidos nesse documento métodos de tratamento de doenças e transtornos responsivos à inibição de pde4, compreendendo a administração de apremilaste e um inibidor de tyk2 a um indivíduo. também são fornecidas nesse documento composições farmacêuticas compreendendo apremilaste e um inibidor de tyk2.combination therapies comprising apremilast and tyk2 inhibitors. provided herein are methods of treating diseases and disorders responsive to pde4 inhibition, comprising administering apremilast and a tyk2 inhibitor to a subject. also provided herein are pharmaceutical compositions comprising apremilast and a tyk2 inhibitor.

BR112021021826A 2019-04-30 2020-04-30 Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition BR112021021826A8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
PCT/US2020/030608 WO2020223431A1 (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (2)

Publication Number Publication Date
BR112021021826A2 BR112021021826A2 (en) 2022-01-04
BR112021021826A8 true BR112021021826A8 (en) 2022-06-21

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021021809A BR112021021809A2 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
BR112021021826A BR112021021826A8 (en) 2019-04-30 2020-04-30 Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112021021809A BR112021021809A2 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (3) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015614A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
AU2022268464B2 (en) * 2021-05-04 2025-04-17 Shanghai Zheye Biotechnology Co. Ltd. Nitrogen-containing heterocyclic pyridine compound
AU2022350509A1 (en) * 2021-09-23 2024-04-04 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
TW201040162A (en) * 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
CA2815330A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
US9272035B2 (en) * 2011-04-28 2016-03-01 Celgene Corporation Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
PL2797581T3 (en) * 2011-12-27 2020-10-05 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EP2802567B1 (en) 2012-01-10 2017-03-01 F. Hoffmann-La Roche AG Pyridazine amide compounds and their use as syk inhibitors
US9187453B2 (en) 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
RU2641895C2 (en) 2012-05-24 2018-01-23 Целльзом Лимитид Heterocyclic pyrimidine analogues as tyk2 inhibitors
CN104903301B (en) * 2012-11-08 2017-08-29 百时美施贵宝公司 Pyrimidine compound available for the alkylamide substitution of regulation IL 12, IL 23 and/or IFN α
CA2890981C (en) * 2012-11-08 2022-07-05 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
HK1215671A1 (en) * 2013-03-14 2016-09-09 细胞基因公司 Treatment of psoriatic arthritis using apremilast
JPWO2015016206A1 (en) 2013-07-30 2017-03-02 武田薬品工業株式会社 Heterocyclic compounds
MX369974B (en) 2013-09-03 2019-11-27 Sareum Ltd Pharmaceutical compounds.
AR094537A1 (en) 2013-11-07 2015-08-12 Bristol Myers Squibb Co PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa
CN105992768B (en) 2013-12-10 2018-04-20 百时美施贵宝公司 The Imidazopyridazine compounds of conditioning agent as the response of IL 12, IL 23 and/or IFN α
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
JP6526065B2 (en) 2014-02-28 2019-06-05 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitors and uses thereof
WO2015200177A1 (en) * 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI744225B (en) 2015-02-27 2021-11-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
LT3419978T (en) 2016-02-24 2020-06-10 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MA46453A (en) 2016-10-07 2019-08-14 Bristol Myers Squibb Co IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS IL-12, IL-23 AND / OR IFN ALPHA RESPONSE MODULATORS
EP3848370B1 (en) 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
IL266109B2 (en) 2016-10-21 2025-05-01 Nimbus Lakshmi Inc TYK2 inhibitors and their uses
CN110114357B (en) 2016-10-28 2022-05-31 百时美施贵宝公司 Hetero-bicyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha response
ES2849974T3 (en) 2016-11-17 2021-08-24 Bristol Myers Squibb Co Imidazopyridazine modulators of IL-12, IL-23 and / or IFNalpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
EP4338802A3 (en) * 2017-03-08 2024-09-04 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
CO2021015614A2 (en) 2021-12-10
BR112021021826A2 (en) 2022-01-04
CN114206333A (en) 2022-03-18
BR112021021809A2 (en) 2022-01-04
SG11202112043PA (en) 2021-11-29
CL2021002847A1 (en) 2022-07-22
MX2021013317A (en) 2022-01-18
MA55799A (en) 2022-03-09
IL287670A (en) 2021-12-01
KR20220002488A (en) 2022-01-06
CN114269336A (en) 2022-04-01
IL287665A (en) 2022-07-01
JP2022537878A (en) 2022-08-31
CO2021015622A2 (en) 2022-02-28
WO2020223431A1 (en) 2020-11-05
KR20220002489A (en) 2022-01-06
CA3138686A1 (en) 2020-11-05
CA3138473A1 (en) 2020-11-05
WO2020222773A1 (en) 2020-11-05
AU2019443366A1 (en) 2021-12-02
SG11202112018YA (en) 2021-11-29
EP3962475A1 (en) 2022-03-09
JP2022537877A (en) 2022-08-31
EP3962476A1 (en) 2022-03-09
MX2021013318A (en) 2022-01-31
CN119454692A (en) 2025-02-18
JP7453251B2 (en) 2024-03-19
AU2020266143A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
BR112021021826A8 (en) Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition
ZA202403923B (en) Heterocyclic compounds as immunomodulators
ZA202204929B (en) Rimegepant for cgrp related disorders
EA202092490A1 (en) METHYL-MODIFYING ENZYMES MODULATORS, COMPOSITIONS AND THEIR APPLICATION
EA202092154A1 (en) COMBINATION THERAPY
MY188048A (en) Indole carboxamide compounds useful as kinase inhibitors
MX391720B (en) COMBINATION THERAPY TO TREAT CANCER.
UY30097A1 (en) THERAPEUTIC USES OF RTP801 INHIBITORS
TN2017000158A1 (en) Carbazole derivatives
BR112021019070A2 (en) tyk2 pseudokinase ligands
WO2016109217A3 (en) Btk inhibitors
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2023002321A (en) TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JANUS ASSOCIATED KINASE (JAK) INHIBITORS.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112021023110A2 (en) Methods of treating sjögren's syndrome with the use of a bruton tyrosine kinase inhibitor
BR112021022602A2 (en) Methods for treating chronic spontaneous urticaria with the use of a bruton tyrosine kinase inhibitor
BR112022000855A2 (en) nlrp3 modulators
BR112021014566A2 (en) gpr35 modulators
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
NO20073104L (en) Use of a 5-HT6 Agonist for the Treatment and Prevention of Neurodegenerative Disorders
BR112018073419A2 (en) combination, use of combination, method for treatment, compound, method for treatment of alzheimer's disease and pharmaceutical composition
BR112022009716A2 (en) DOSAGE OF A BRUTON TYROSINE KINASE INHIBITOR
BR112022012081A2 (en) METHOD TO TREAT CANCER, KIT, AND, USE OF A THERAPEUTIC COMBINATION
BR112021006424A2 (en) tyk2 kinase inhibitors